



Monkeypox Re-Emergence after Covid-19 Crisis

Hussain S^{1*}, Tyagi S², Kaur G³, Kataria T³, Singh M¹, Kumari P¹ and Himanshi Khatri¹

¹School of Pharmaceutical Sciences, Jaipur National University, India

²Department of Pharmacy, Quantum School of Health Sciences, Quantum University, India

³School of Pharmaceutical Sciences, Lovely Professional University, India

*Corresponding author: Sadique Hussain, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan 302017, India; Email: sadiquehussain007@gmail.com

Mini Review

Volume 6 Issue 1

Received Date: June 06, 2022

Published Date: June 23, 2022

DOI: 10.23880/beba-16000170

Abstract

Several contagious illness outbreaks have devastated the globe over the past. With the plethora of potential and reappearing infections such as MXP on the upswing, it is past time to draw lessons and insights from previous outbreaks to guide and effectively prepare for potential future outbreaks. Monkeypox (MXP) is a new zoonotic disease that has emerged as the most common orthopoxvirus infection in people since the elimination of smallpox. MXP's clinical manifestations are identical to that of smallpox. The illness is endemic in the Democratic Republic of the Congo (DRC), although other nations in Central Africa (CA) and West Africa (WA) have documented human cases or wildlife transmission. The MXP was also identified for the first time in the United States (US) in 2003. The condition has long been thought to be uncommon and self-limiting, although infrequent cases imply differently. Regrettably, the information gathered is scarce, fragmented, and sometimes inaccurate. Human MXP cases have grown in incidence and regional distribution in past years because there are significant gaps in knowledge of the condition's origin, epidemiology, and biology. The MXP virus is an elevated virus that infects a serious public-health problem. As a result, there seems to be a necessity to emphasize developing surveillance capabilities that will give vital data for establishing suitable preventative, readiness, and response operations.

Keywords: Zoonotic; Smallpox; Orthopoxvirus; MXP Emergence; Covid

Introduction

The occurrence of zoonotic infection epidemics poses a serious threat to human health. Several viral infections with pandemic potential pose a hazard to public health. Zoonotic infections, in particular, have been responsible for multiple outbreaks in past years, resulting in significant incidence and fatality [1,2]. The COVID-19 catastrophe demonstrated that any viral epidemic capable of transmitting person-to-person or cross-species transmission might pose a major risk and lead to a worldwide outbreak. Many nations have yet to

emerge entirely from the COVID-19 problem [3-5]. Though some teachings are being learned out of each pandemic, repeated epidemics of new or reappearing infection serve as a cue that zoonotic diseases will proceed to arise; thus, a successful international zoonotic disease monitoring system combined with an immediate change to endemic could reduce the chance of cross-border transmission [6]. After surviving the COVID-19 outbreak for more than a couple of years, a new zoonotic MXP virus has been detected in several non-endemic nations lately. While it is an uncommon, self-limiting infection that is generally weaker than smallpox

and is not a cause for alarm at this time, early discovery and prompt action are crucial for viral control [7].

The MXP virus, which was discovered about six decades ago, is a member of the Orthopoxvirus genus, which also includes variola virus (the causative agent of smallpox), vaccinia virus, and cowpox virus. It was initially derived from pox lesions in 1958, thus the name MXP [8]. Between 1970 and 2017, multiple breakouts and low incidence were documented in CA, Cameroon, Congo Brazzaville, Côte d'Ivoire, DRC, Gabon, Liberia, Nigeria, Sierra Leone, and South Sudan, among other places. Since the elimination of smallpox in 1980, MXP has steadily evolved as the most significant orthopoxvirus in terms of human health, owing to its prevalence in humans [9,10].

In 1970, a 9-year-old girl in the DRC was recognized as the very first individual case [11,12]. Since then, there have been intermittent instances of human MXP, primarily in CA and WA Figure 1. The first MXP epidemic outside of Africa was discovered in the US in 2003, following the importation of diseased animals from Ghana [13,14].




Figure 1: Timeline of the MXP virus.

Clinical Features

MXP is a viral illness that causes clinical symptoms in people that are comparable to those described in previous smallpox cases [15,16]. The majority of patients get a fever at first, accompanied by a rash just a few days later. Lymphadenopathy is a typical symptom that appears immediately before or concurrently with the rashes [17]. Secondary bacterial infections, respiratory distress, bronchopneumonia, gastrointestinal involvement, dehydration, sepsis, encephalitis, and corneal infection with resulting loss of vision are all possible consequences.

There is presently no particular therapy for MXP infection, and individuals are handled with supportive therapy and symptomatic medication [18].

Data from verified MXP patients in Nigeria and the US imply that the primary clinical symptoms in each locale are comparable Table 1.

Clinical Features	United States	Nigeria
Fever	73	88
Headache	33	79
Lymphadenopathy	47	69
Rash	83	100
Sore Throats	33	58

Table 1: Evaluation of clinical characteristics seen in MXP patients from 2 nations (n=122 in Nigeria and 30 in the US).

The key characteristic found is rashes (100 percent and 83 percent), whereas sore throat is the less prevalent (58 percent and 33 percent). Depending on the number of individuals with relevant data, proportions were determined for each attribute separately [19].

The incubation phase normally lasts 6 to 13 days, although it can last up to 21 days. Rodents are most probably the MXP virus's reservoir. Person-to-person spread occurs via droplets in the air, bodily fluids, contact with a lesion, damaged skin, and infected surfaces or other objects such as mattresses and clothes Figure 2 [20,21].




Figure 2: Transmission of the MXP virus.

Genus

The human MXP virus has been classified into two variants: the WA variant and the Congo Basin (CB) variant [11,5]. The WA strain has a mortality rate > 1%, and no

person-to-person spread has ever happened on record. However, when we relate the CB strain to this one, we can observe that the mortality rate can significantly rise to 11% [22-25].

Re-Emergence

Following the verified case of the WA strain of MXP announced on 7 May 2022 in the United Kingdom (UK) and several nations subsequently, international interest has been focused on the MXP infection. The infected individual had previously visited Nigeria and returned to the UK. Before this current epidemic, the most recent cases were recorded in 2021. According to the UK Health Security Agency, viral spread was detected in Europe this time without any epidemiologic ties, trip record to Africa, or documented contact with an affected individual. Cases have been documented in Australia, Canada, Israel, and various European nations, including the UK, Sweden, Spain, Portugal, the Netherlands, Italy, Germany, Belgium, France, and the US [8]. A large number of infected patients are being examined. As a result, there is still the chance of finding further instances in non-endemic nations. More than 100 verified cases have been discovered outside of Africa. However, no deaths have been reported in 2022 thus far. All cases recorded outside of Africa have been caused by the WA clade. The natural history, animal origin, and reservoir host for viral circulation are all unknowns. Extensive surveillance of the MXP virus in endemic areas will help in understanding the virus's zoonotic source [9].

MXP often presents with a rash, lymph node enlargement, and fever, and most infected persons recover within a few weeks. When a reported or verified new case is identified, appropriate segregation with supporting management and quarantine procedures should be in place to respond immediately [25-29]. The discontinuation of smallpox vaccination in 1980, as well as declining antibody among the public and a rising number of unvaccinated persons, resulted in a rise in the prevalence of MXP [10]. Smallpox immunization is beneficial against MXP. Furthermore, MVA-BN (JYNNEOS in the US, IMVAMUNE in Canada, and IMVANEX in Europe) is the only licensed vaccine for the prophylaxis of MXP, and Tecovirimat SIGA (Tpoxx) is a drug approved for the treatment [13].

Though it is still a pretty uncommon virus, the large majority of MXP infections in non-endemic regions and throughout Europe is causing concern around the globe. Epidemiological studies, transmission dynamics, and illness ecology are not well known and require further study. To cope with rising or sustainably resurging highly contagious hazards, awareness campaign ideas, boosting safety precautions, instructing medical workers, progressing global

health readiness with assertive constant comprehensive vigilance, fast hazard identification, response planning, early diagnosis, and contact tracing ought to be essential. The COVID-19 catastrophe emphasizes the need to enhance socialized health care services as well as develop global rules and regulatory frameworks to respond rapidly to future threats [11].

Conclusion

It is past time to begin taking steps to avoid and plan for outbreaks, particularly for viruses that have been identified as substantial human dangers, such as MXP. The data presented in this paper illustrate how little and scattered knowledge regarding MXP distribution remains, perhaps leading to an underestimating of the frequency and variety of MPX events. This should serve as a wake-up signal to the science establishment to increase their involvement, follow-up, and study on this condition. Although first identified in 1958 and documented in 1970 in a person for the first time, there have been no conventional recommendations for patient care, medications, or vaccinations. This is also an emergency appeal for leaders in the healthcare system to accept responsibility for sharing information with health authorities and communicating honestly with the community as early as feasible. MXP is a major health issue for individuals of endemic areas such as the DRC and other African nations where virus flow has been proved, but it is also an international health security issue, as evidenced by the 2003 outbreak in the US. Efficient and suitable treatments, as well as continuous monitoring, are immediately required to avoid enhanced transmission rate or pathogenicity.

India developed a few of the guidelines that are to be followed by each state regarding the MXP. The World Health Organization and other government agencies are collecting intelligence, evaluating information gaps, and prioritizing research problems for MXP investigation in terms of developing an immediately deployable response to prevent the occurrences. Overall, the epidemic must be closely watched, treatment alternatives and measures to control investigated, and the population encouraged following the safety procedures given by national and international health authorities.

References

1. Stephenson J (2003) Nutritional and therapeutic potential of sunflower seeds: a review. *JAMA* 290: 23-24.
2. Hussain S, Tyagi S, Kaur G, Bahl G (2022) The Evolving COVID-19: Omicron. *International Journal of Biomed Research* 2(6).

3. Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, et al. (2019) Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. *International Journal of Infectious Disease* 78: 78-84.
4. Hussain MS (2022) Covid-19 Vaccine Efficacy on Omicron Variant. *Bioequivalence & Bioavailability International Journal* 6(1): 2.
5. Hussain S (2021) Targeting SARS-CoV-2 with therapeutic monoclonal antibodies. *Precision Medicine Research* 3(4): 18.
6. Zumla A, Valdoleiros SR, Haider N, Asogun D, Ntoumi F, et al. (2022) Monkeypox outbreaks outside endemic regions: scientific and social priorities. *Lancet Infectious Diseases*.
7. Ntoumi F, Zumla A (2022) Advancing accurate metrics for future pandemic Preparedness. *Lancet*. 399(10334): 1443-1445.
8. Magnus PV, Andersen EK, Petersen KB, Birch-Andersen A. (1959) A pox-like disease in *Cynomolgus* monkeys. *Acta pathologica et microbiologica Scandinavica* 46(2): 156-176.
9. Doshi RH, Guagliardo SAJ, Dzabatou-Babeaux A, Likouayoulou C, Ndakala N, et al. (2018) Strengthening of Surveillance during Monkeypox Outbreak, Republic of the Congo, 2017. *Emerging Infectious Diseases*. 24(6): 1158-1160.
10. Silenou BC, Tom-Aba D, Adeoye O, Arinze CC, Oyiri F, et al. (2020) Use of Surveillance Outbreak Response Management and Analysis System for Human Monkeypox Outbreak, Nigeria, 2017–2019. *Emerging Infectious Diseases* 26(2): 345-349.
11. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, et al. (1980) Human MXP, 1970-79. *Bull World Health Organ* 158(2): 165-182.
12. Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, et al. (2018) Reemergence of Human Monkeypox in Nigeria, 2017. *Emerging Infectious Diseases* 24(6): 1149-1151.
13. Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR (2021) Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017–2020. *Emerging Infectious Diseases* 27(4): 1007-1114.
14. Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, et al. (2019) Diagnosis of Imported Monkeypox, Israel, 2018. *Emerging Infectious Diseases*. 25(5): 980-983.
15. Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, et al. (2010) Human Monkeypox Outbreak Caused by Novel Virus Belonging to Congo Basin Clade, Sudan, 2005. *Emerging Infectious Diseases*. 16(10): 1539-1545.
16. Nakazawa Y, Emerson GL, Carroll DS, Zhao H, Li Y, et al. (2013) Phylogenetic and Ecologic Perspectives of a Monkeypox Outbreak, Southern Sudan, 2005. *Emerging Infectious Diseases* 19(2): 237-245.
17. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, et al. (2016) Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo. *Emerging Infectious Diseases*. 22(6): 1014-1022.
18. Reynolds MG, McCollum AM, Nguete B, Lushima RS, Petersen BW (2017) Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. *Viruses* 9(12): 380.
19. Oladoye MJ (2021) Monkeypox: A Neglected Viral Zoonotic Disease. *European Journal of Medical and Educational Technologies* 14(2): em2108.
20. Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, et al. (2019) MXP-Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. *International Journal of Infectious Diseases* 78: 78-84.
21. WHO (2022) MXP-United Kingdom of Great Britain and Northern Ireland.
22. Beer EM, Rao VR (2019) A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Neglected Tropical Diseases* 13(10): e0007791.
23. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, et al. (2022) The changing epidemiology of human MXP-A potential threat? A systematic review. *PLoS Neglected Tropical Disease* 16(2): e0010141.
24. Singh NP, Sharma S, Ghai G, Singh A (2021) A Systematic Review on Epidemiology of Human Monkeypox Virus. *Annals of RSCB* 25(7): 602-610.
25. (2022) Health Security Agency. MXP cases confirmed in England-latest updates, UK.
26. WHO (2022) Multi-country MXP outbreak in nonendemic

countries.

27. Sklenovská N, Van Ranst M (2018) Emergence of MXP as the most important orthopoxvirus infection in humans. *Front Public Health* 6: 241.
28. Volkman A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, et al. (2021) The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. *Vaccine* 39(22): 3067-3080.
29. Shanmugaraj B, Malla A, Khorattanakulchai N, Phoolcharoen W (2022) SARSCoV- 2 omicron variant: Could it be another threat? *Journal of Medical Virology* 94(4): 1284-1288.

